AMG 193, IDE397, AMG 193, IDE397, AMG 193
20220127
Phase 2 small_molecule active
Quick answer
AMG 193, IDE397, AMG 193, IDE397, AMG 193 for In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer is a Phase 2 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active